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1. Introduction 
Melanoma is one of the most serious forms of cutaneous malignancies with an incidence of 
over two million people worldwide1. During 2010, an estimated 68,130 new patients were 
diagnosed with melanoma, and 8,700 deaths were attributed to the development of 
metastatic disease in the United States2. Compared to earlier stages of melanoma, the 
prognosis for patients with metastatic (stage IV) melanoma is very poor with six out of 
every seven skin cancer-related deaths being attributed to melanoma. However, our 
diagnostic and prognostic methods for melanoma are primarily histologic, such as Breslow’s 
depth of invasion, falling far short of being able to accurately predict the overall survival, 
recurrence risk, or clinical outcomes for patients3. There are several methods of treatment for 
metastatic melanoma, including radiation therapy, immunotherapy, chemotherapy, and 
palliative surgery2, 4, 5. However, there exists a clear and unfortunate understanding that 
these therapies are only minimally effective in treating patients with advanced disease6.  
MicroRNAs(miRNAs) are a set of small, average 22 nt in length, single-stranded, non-protein-
coding RNA molecules that can recognize and bind 3’-untranslated regions (UTR) of mRNA, 
blocking translation of the gene or inducing cleavage of the mRNA7, 8. To date, a total of 15,172 
miRNAs (Version 16.0), including 1,049 human miRNAs, have been registered in the miRbase 
database. The biogenesis of miRNA is similar to the other RNA starting from DNA 
transcription. A primary miRNA (pri-miRNA) is an independent transcript processed by RNA 
polymerase II (Pol II), which are bound in the nucleus by the microprocessor complex 
consisting of the RNase III-type endonuclease, Drosha, and its co-factor, Pasha (DGCR8).  
These enzymes can crop the pri-miRNA into a hairpin loop, cleaving off 3’ and 5’ regions of 
excess mRNA to give precursor miRNA (pre-miRNA) ~70 nt in length. Pre-miRNA is then 
actively transported to the cytoplasm by exportin-5 where it is bound by the RNAse III-type 
endonuclease, Dicer, which removes the loop, resulting in a duplex of complementary, mature 
miRNA sequences. One strand is bound by the RNA-induced silencing (RISC) complex, which 
guides mature miRNA to target mRNA for subsequent silencing. The remaining strand is 
usually degraded, but it may be bound by RISC and target its own mRNAs, which are denoted 
with an asterisk (i.e., miR-10b and miR-10b*)9, 10.  
In both plants and animals, miRNAs are capable of mediating gene expression by 
influencing the RNA’s stability and/or translational resspression11, 12. Impressively, a single 
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miRNA can potentially bind hundreds to thousands of its cognate mRNA 3’UTR sequences. 
It is predicted that miRNAs may regulate upwards of 30% of all mammalian genes’ 
expression, due to their critical function in gene regulation and expression8. Thus, it is 
meaningful to understand their roles and significance in the essential cellular events, such as 
development, differentiation, proliferation, and apoptosis, which account for carcinogenesis, 
tumor progression, and metastasis13-16. MiRNA synthesis and function is summarized in 
Figure 1. 
 
 
Fig. 1. MicroRNA biogenesis and biological functions 
Following a pilot study connecting B-cell chronic lymphocytic leukemia (CLL) and 
deregulated expression of miR-15a and miR-16-117, it has been demonstrated that more than 
50% of miRNA genes are located in cancer-associated genomic regions or within fragile 
sites18, and more and more miRNAs have been identified to play a central role in the 
pathogenesis of human cancers. Although it was in 2006 that the first study on miRNA in 
melanoma has reported that 86% of primary melanoma cell lines had DNA copy number 
alterations in genomic loci containing miRNA genes19, studies focusing on the roles of 
miRNA in the pathogenesis and development of melanoma have bloomed since 2008. 
Figure 2 illustrates the miRNAs reported by more than two studies or confirmed by 
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functional studies in the progression of melanoma20-26, suggesting that miRNAs play an 
important role in melanocyte and melanoma biology. To date, there are 77 publications that 
can be retrieved in PUBMED when using keywords “melanoma and miRNA”; more than 
99% of them were published in the latest three years, and half of them were published from 
2010 to 2011, which is evidence that this research field is rapidly expanding. However, a few 
knowledge and understanding gaps need to be filled before taking full advantage of miRNA 
signatures in melanoma research. In 2010, we were invited to author a review summarizing 
the accomplishments on the research of miRNA and melanoma27. Here, based on the 
previous review, we will highlight the latest progress in this field.  
 
 
Fig. 2. Representative miRNAs involved in the progression of melanoma 
2. Oncogenic miRNAs in melanoma 
The role of miRNAs in tumorigenesis depends on their target genes’ classification and 
abundance. When targeting tumor suppressor genes, these over-expressed miRNAs will 
play the promoting tumor roles as oncogenes; likewise, when targeting oncogenes, these 
miRNAs will have the characteristics of tumor suppressors. Kitago et al. reported that miR-
532-5p directly targeted the runt-related transcription factor 3 (RUNX3) tumor suppressor 
during the progression from melanocyte to metastatic melanoma28. MiR-532-5p was shown 
to be significantly up-regulated in melanoma cells compared to normal melanocytes and in 
metastatic melanoma tissue compared to primary melanoma tissue. The transfection of anti-
miR-532-5p molecules to the melanoma cells rescued the expression of RUNX3. Methylation 
analysis of the RUNX3 promoter region showed that transcriptional regulation was not a 
major regulatory mechanism for the down-regulation of RUNX3 expression in melanoma, 
suggesting miR-532-5p induced post-transcriptional regulation played an important role in 
melanoma progression. 
Zhang et al. demonstrated that the expression of miR-210, the most prominent miRNA up-
regulated by hypoxia and a direct transcriptional target of hypoxia inducible factors (HIFs), 
was elevated in multiple cancer types and correlated with breast cancer and melanoma 
metastases, respectively. MiR-210 over-expression in cancer cells bypassed hypoxia-induced 
cell-cycle arrest by directly targeting the expression of MNT, which is a gene known as one of 
the Myc antagonists. The miR-210-mediated abolishment of hypoxia-induced cell-cycle arrest 
was restored by the loss of Myc5. This finding indicated that miR-210 influenced the hypoxia 
response in tumor cells by triggering a Myc-like response by targeting MNT expression. 
The miR-200 family has received much attention for suppressing epithelial-mesenchymal 
transition (EMT) as well as their down-regulation in some tumors promotes invasion and 
metastasis. Interestingly, Elson et al. showed that levels of miR-200 are increased in 
melanoma cell lines compared to normal melanocytes. In melanoma cell lines, the 
expression of miR-200 members has no significant effect on suppressing invasion but 
www.intechopen.com
 
Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
6 
instead leads to a switch between modes of invasion. For example, miR-200c results in a 
higher proportion of cells thus adopting the rounded, amoeboid-like mode of invasion by 
reduced expression of myristoylated alanine-rich protein kinase C substrate (MARCKS); 
meanwhile, miR-200a results in a protrusion-associated elongated mode of invasion by 
reduced actomyosin contractility. This study improved our understanding of the impacts of 
the miR-200 family on suppressing invasion and metastasis, and implied a novel insight of 
these miRNAs in melanoma29.  
3. Tumor suppressor miRNAs in melanoma 
Recently, miR-34 was identified as a target and a potential key responder of the tumor 
suppressor gene product, p53. Ectopic expression of miR-34a induced a G1 cell-cycle arrest, 
senescence, and apoptosis, which suggested that miR-34 was a potential tumor suppressor12. 
The altered expression of miR-34 was also found in melanoma progression22, 24, 30. Lodygin 
et al. reported that miR-34a expression is silenced in several types of cancer due to the 
aberrant CpG methylation of its promoter. Reportedly, 43.2% of melanoma cell lines and 
62.5% of primary melanoma samples displayed CpG methylation of the miR-34a promoter 
and loss of miR-34a expression, whereas the two samples of normal melanocytes included in 
the study did not show promoter methylation30. Migliore et al. identified three miRNAs, 
miR-34b, miR-34c, and miR-199a*, in melanoma cells that negatively regulate the expression 
of MET, which is an oncogene that encodes the tyrosine kinase receptor for hepatocyte 
growth factor24. MET is frequently over-expressed in many human tumors and promotes the 
‘invasive growth’ that results from the stimulation of cell motility and protection from 
apoptosis. Exogenous expression of these miRNAs in primary melanoma cells led to a 
decreased MET protein expression and resulted in the impairment of MET-mediated 
motility in these cells24. Recently, Yan et al. detected the expression level of miR-34a in uveal 
melanoma cells and melanocytes and found that miR-34a had been actively expressed in 
melanocytes but not in uveal melanoma cells. Additionally, the transfection of miR-34a into 
melanoma cells led to a significant repression of their growth and migration by down-
regulating the expression of c-Met directly and the expression of phosphorylated Akt (p-
Akt) and other cell-cycle-related proteins indirectly 22.  
Mazar et al. found the levels of miR-211 were reduced in melanoma cell lines compared 
with expression levels in melanocytes. Ectopically expressing miR-211 in different 
melanoma cell lines caused significant growth inhibition and reduced invasiveness by 
cleaving the mRNA and inhibiting the translation of KCNMA1, a highly expressed protein 
in metastasizing melanoma, prostate cancer, and glioma31. Another research study resulted 
in a similar but more interesting conclusion. MiR-211 is encoded within the sixth intron of 
TRPM1, which is known as melastatin and is greatly down-regulated in metastatic 
melanomas; it is widely believed to function as a melanoma tumor suppressor. Levy et al. 
reported that the tumor suppressive activity of TRPM1 in melanoma is not mediated by this 
gene itself but instead by miR-211 hosted within an intron of TRPM1 because of the 
increasing expression of miR-211 but not a TRPM1 reduced migration and invasion of 
invasive human melanomas cells. This result implicates miR-211 as a suppressor of 
melanoma invasion whose expression is silenced or selected against via the suppression of 
the entire TRPM1 locus during human melanoma progression. Additionally, they also 
identified three central node genes, IGF2R, TGFBR2, and NFAT5, as the target of miR-21132. 
Notably, the micropthalmia-associated transcription factor (MITF), which is important for 
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melanocyte development and function, is needed for high TRPM1 expression31, and thus, 
MITF contributes to miR-211 expression, suggesting that the tumor-suppressor activities of 
MITF may at least be partially executed through miR-211's tumor suppressing effect.  
MiR-196a is another documented tumor suppressor in melanoma by Dr.Bosserhoff’s group 
33, 34. First, they found that miR-196a was significantly down-regulated in malignant 
melanoma cell lines and tissue samples when screening differential miRNAs. Re-expressing 
miR-196a in vitro can dramatically reduce the invasive behavior of melanoma cells, which is 
partially believed to account for the negative regulating expression of the transcription 
factor HOX-C8, which is a member belonging to the homeobox genes family. By 
investigating a potential “miR-196a → HOX-C8 → target gene” model, they further 
identified cadherin-11, calponin-1, and osteopontin as the downstream targets of miR-
196a34. Additionally, they elucidated that down-regulated miR-196a in melanoma cells leads 
to enhanced HOX-B7 mRNA and protein levels, another member of the homeobox genes 
family, which subsequently raise Ets-1 activity, another transcription factor, by inducing 
basic fibroblast growth factor (bFGF). Ets-1 eventually up-regulates bone morphogenetic 
protein 4 (BMP-4)  playing an important role in melanoma progression33. 
Chen et al. reported that the over-expression of miR-193b in melanoma cell lines repressed 
cell proliferation by down-regulating cyclin D1 (CCND1). They identified 31 miRNAs that 
are differentially expressed (13 up-regulated and 18 down-regulated) in metastatic 
melanomas relative to benign nevi by profile-analyzing tissue samples from benign nevi and 
metastatic melanomas. Notably, miR-193b was significantly down-regulated in the 
melanoma tissues examined. Functional studies revealed miR-193b is a tumor suppressor in 
melanoma. Their study indicates that miR-193b is able to repress cell proliferation and 
regulate CCND1 expression, suggesting that the deregulation of miR-193b may play an 
important role in melanoma development35. 
4. Molecular mechanism of microRNA associated with melanoma 
The development of rational treatments for melanoma will depend on our taking advantage of 
its clinical features’ molecular basis. The necessary understanding of the molecular genetics 
underlying melanoma is gradually emerging36. Many key genes and signaling pathways have 
been characterized for their functions associated with melanoma. For example, the 
micropthalmia-associated transcription factor (MITF) is one of the most recognizable 
oncogenes in melanoma, which regulates cell proliferation and apoptosis, and is over-
expressed in 10-20% of human melanoma32. Also, it is a member in Myc supergene family of 
basic helix-loop-leucine-zipper transcription factors, which are necessary for functional 
melanocyte formation37. Because MITF’s critical role in melanoma progression, several recent 
studies have explored miRNAs’ impact on melanoma through MITF mediated pathways.   
4.1 MicroRNAs targeting MITF  
MicroRNA.org, an online database for miRNA targets prediction, provides more than 300 
miRNA candidates that putatively target MITF. However, only few of them have been 
verified.  
MiR-137 is located in the chromosomal region, 1p22, which is known to harbor an allele for 
melanoma susceptibility. The bioinformatics and in vitro analyses verified that miR-137 had 
targeted MITF in melanoma cells20. Most recently, Chen et al. reported the down-regulation 
of MITF by miR-137 in uveal melanoma cells38. Additionally, the over-expression of miR-137 
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in uveal melanoma cells can lead to a significant decrease in cell growth through inducing 
G1 cell cycle arrest, which might be due to its suppression on oncogenic tyrosine kinase 
protein receptor c-Met, cell cycle-related protein CDK6, and MITF38.  
Segura et al. described miR-182 also as a negative regulator of MITF expression25. MiR-182 is 
located in 7q31-34, a chromosomal region frequently altered in melanoma. MiR-182 was 
demonstrated to increase the invasive potentials of melanoma cells by repressing MITF and 
FOXO3, a Forkhead family transcription factor. Importantly, 7q31-34 also harbors c-Met 
(encodes hepatocyte growth factor receptor with tyrosine-kinase activity) and BRAF 
(member of the raf/mil family of serine/threonine protein kinases), two important 
regulators in the MAPK/ERK signaling pathway39. They found that miR-182 was over-
expressed not only in human melanoma cell lines but also in tissue specimens. These results 
were inversely correlated with MITF and FOXO3 expression in the prediction of melanoma 
progression and development. Moreover, miR-182 ectopic expression in melanoma cells 
stimulated the anchorage-independent growth and invasion using an in vitro extracellular 
matrix assay, and promoted melanoma lung metastasis in a mouse model, whereas miR-182 
down-regulation impeded invasion and triggered apoptosis of melanoma cells.  
MiR-340 is capable of causing mRNA degradation by interacting with its 3'-UTR of MTIF. 
Interestingly, the RNA-binding protein coding region determinant-binding protein (CRD-
BP) is highly expressed in melanoma and can directly bind the 3'-UTR of MITF mRNA thus 
preventing miR-340 access, resulting in the stabilization of the MITF transcript and the 
elevation the transcription of MITF40.  
4.2 MiRNAs regulated by MITF in transcription 
As described earlier, miRNA has a similar transcription and regulatory process to other 
RNA molecules. MITF has been demonstrated as a transcriptional factor37.  Ozsolak et al. 
identified a number of miRNAs that were regulated by MITF in melanoma cells using 
nucleosome mapping and linker sequence analyses41. These miRNAs included some 
members of let-7 family (let-7a-1, -7d, -7f-1 and -7i), miR-221/222, miR-17-92 cluster, miR-
106-363 cluster, miR-29, miR-146a, miR-148b and miR-125b41. A few of them, such as let-7, 
miR-17-92, miR-221/222, and miR-148, have been documented for their abilities to connect 
many key genes and to signal pathways to melanoma. Here, we will illustrate a MITF-
centered regulatory loop with the involvement of multiple miRNAs/mRNAs/pathways 
(Figure 3). 
 
 
Fig. 3. Molecular mechanism of microRNA regulation in melanoma  miRNA 
target gene transcription factor  
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The Let-7 family is highly conserved across species in sequence and function, which were 
first validated to be involved in tumorigenesis42. Schultz et al. revealed five members of the 
let-7 family (let-7a, -7b, -7d, -7e, and -7g) as being significantly down-regulated in primary 
melanoma when compared with benign nevi, which suggested that the let-7 family might be 
tumor suppressors in melanoma43. The ectopic over-expression of let-7b diminished the 
anchorage-independent growth ability of melanoma cells and inhibited the cell-cycle 
progression. The over-expression of let-7b eventually repressed cyclins (D1, D3 and A) and 
cyclin-dependent kinase (CDK4) all of which had been described to play a role in melanoma 
development. Most recently, another study showed that the over-expression of let-7b in the 
melanoma cell line B16-F10 exhibited an inhibition of both cellular proliferation and colony 
formation. Let-7b can reduce lung metastasis by repressing the expression of basigin, which 
is a stimulator for tumor cells producing matrix metalloproteinases (mmps) and is highly 
expressed on the surface of tumor cells44. 
Let-7a is considered lost in melanoma when one is comparing primary melanocytes to 
malignant melanoma cell lines. Sequencing analysis suggested Let-7a had an interaction 
with the 3'UTR of integrin β3 mRNA26. Integrin β3 is highly related to melanoma 
progression and leads to an enhanced migratory and an enhanced invasive potential of 
melanoma cells45. The transfection of melanoma cells with let-7a pre-miR molecules resulted 
in the down-regulation of integrin β3 mRNA and protein expression, which suggested that 
the loss of let-7a expression might be one of the essential regulatory mechanisms leading to 
an increase integrin β3 expression in melanoma cells26. Muller et al. also proved that the 
over-expression of let-7a in melanoma cells reduced their invasive potential by 
approximately 75%; meanwhile transfection with let-7a anti-miRs and anti-sense 
oligonucleotides that directly binds and inhibits the actions of miRNAs, resulted in the 
induction of the integrin β3 expression and induced the migration of anti-let-7a-transfected 
melanocytes. These findings revealed let-7a to be an important integrin β3 regulator, and the 
loss of let-7a is thus involved in the development and progression of malignant melanoma. 
The miR-17-92 cluster locates to chromosome 13 and contains 6 members (miR-17, -18a, -19a, 
-20a, -19b-1 and -92a-1), while another  miRNA cluster, miR-106-363that shares many 
similarities with the miR-17-92 cluster locates to the X chromosome; it also consists of 6 
members (miR-106a, -18b, -20b, -19b-2, -92a-2 and -363). Both miRNA clusters are described 
as being oncogenic and found to be highly expressed in a variety of cancers46, 47. Muller et al. 
compared the miRnomes of normal human melanocytes and well characterized melanoma 
cell lines derived from primary tumors and melanoma metastases and showed that all 
members of the miR-17-92 cluster were up-regulated in primary tumor cell lines compared 
with normal melanocytes. The expression of the miR-17-92 cluster was even higher in 
metastatic cell lines with an approximately two-fold up-regulation as compared to primary 
melanoma cell lines. The expression of the miR-106-363 cluster was similar to the expression 
of the miR-17-92 cluster in melanocytes and melanoma cells. They detected a strong up-
regulation of miR-106a expression in primary tumor cells and a further increase in 
expression levels in metastatic melanoma cells48. In addition to finding miR-17-5p, miR-18a, 
miR-20a, and miR-92a over-expressed and miR-146a, miR-146b, and miR-155 down-
regulated in the majority of melanoma cell lines with respect to melanocytes, Levati et al. 
found that ectopic expression of miR-155 in melanoma cells inhibits the proliferation49. 
These results imply that the miR-17-92 cluster would be involved in melanoma progression. 
Both miR-221 and miR-222 are regulated by MITF at the transcription level21. These two 
miRNAs are clustered on the X chromosome, are transcribed as a common precursor, and 
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are over-expressed in a variety of cancers with the function of repressing the c-Kit receptor. 
In normal melanocytes, stem cell factor (SCF)-dependent c-Kit-mediated signaling supports 
proliferation, migration, and differentiation of cells50. Constitutive activation of c-Kit receptor 
tyrosine kinase (RTK) alone does not induce a tumorigenic transformation of the melanocytes 
in neither in vitro nor in vivo51; however, cutaneous melanoma are often characterized with a 
loss of c-Kit expression52. The inhibition of c-Kit RTK in c-Kit-positive melanoma showed an 
increased apoptosis and G1 phase cell-cycle arrest52, while the re-expression of c-Kit in the c-
Kit-negative melanoma cells restored c-Kit-mediated apoptosis and resulted in a loss of 
tumorigenic potential53. In accordance with these observations, Felicetti et al. found that up-
regulated miR-221/222 repressed the expression of the c-Kit receptor and p27Kip1 (cyclin-
dependent kinase inhibitor 1B, CDKN1B) tumor suppressor during melanoma progression 
from a weakly invasive primary tumor to a more invasive phenotype21. The over-expression of 
miR-221/222 in melanoma cells led to an increase in their proliferation and invasion in vitro 
and accelerated tumor growth in a mouse melanoma model. Conversely, treatment with anti-
miRs against both miRNAs resulted in a reduced proliferation rate and migration of 
melanoma cells with a high level of miR-221/222 abilities. They also found that the elevated 
expression of miR-221/222 in melanoma cells was caused by the loss of a transcription factor, 
promyelocytic leukemia zinc finger (PLZF). PLZF binds to the miR-221/222 promoter and 
inhibits their transcription in normal melanocytes.  
Cyclin-dependent kinase 2 (CDK2) has been reported to phosphorylate PLZF, triggering its 
ubiquitination and subsequent degradation54. Furthermore, p27Kip1 is important for the 
efficient induction of G1 cell-cycle arrest by PTEN and is necessary for PTEN-induced 
down-regulation of CDK2 55, 56. Additionally, PTEN is an inhibitor for Ha-ras-mediated 
astrocyte elevated gene-1 (AEG-1) transactivation 57. AEG-1 directly binds PLZF, preventing 
it from binding its target promoters58, including those of miR-221/222. Therefore, PTEN 
may be an important negative regulator of miR-221/222 in melanoma as it is capable to 
maintain PLZF levels to bind the miR-221/222 promoters, preventing their transcription. 
Although there are no miRNAs currently described to target PTEN in melanoma, recent 
reports highlighted miR-221/222 in aggressive non-small cell lung cancer (NSCLC) and 
hepatocarcinoma as oncomirs capable of directly targeting and inhibiting the expression of 
the tumor suppressor, PTEN 59, 60. As a result, there may be a positive feedback loop for 
miR-221/222 expression, promoting melanoma progression through the joint inhibition of 
PTEN and p27Kip1 and blocking PTEN/AEG-1/PLZF and/or p27Kip1/CDK2/PLZF-
mediated repression of miR-221/222. 
Additionally, Igoucheva et al. confirmed that c-Kit was down-regulated by miR-221/222 
and revealed that c-Kit regulation was mainly based on miRNA-dependent post-
transcriptional mechanisms instead of an AP-2-dependent transcriptional mechanism50. 
Recently, mutations have been identified in both miRNAs and target genes that disrupt 
regulatory relationships. Godshalk et al. described a genetic variant in the 3' UTR of the KIT; 
this KIT variant results in a mismatch in the seed region of a miR-221 complementary site 
and thus leads to an increased expression of the KIT oncogene 61. 
Haflidadóttir et al. suggested that miR-148 affects MITF mRNA expression in melanoma 
cells through a conserved binding site in the 3'UTR sequence of mouse and human MITF37. 
Interestingly, it seemed that MITF transcriptionally regulated the expression of miR-148b in 
melanoma cells41, which showed that there was a negative feedback regulation between 
miR-148 and MITF to control their balance.  
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5. Clinical applications of miRNA in melanoma  
5.1 Diagnostic miRNAs 
Several years ago, we and other groups independently demonstrated that miRNAs were 
relatively more stable and tolerate RNAases better than mRNAs in both archived tissue 
samples and in blood samples27, 41, 62, which suggests that miRNAs have the potential to be 
valuable, practical, and reliable biomarkers for disease states.  
Recently, several groups employed a high through-put microarray technique to discover 
miRNA biomarkers from formalin-fixed and paraffin-embedded (FFPE) melanoma 
samples9, 63, 64. A number of miRNAs have shown the potential to become diagnostic 
markers for melanoma based on data from clinical samples and array analysis9, 63, 
64.Radhakrishnan et al. examined the presence of oncogenic miRNA (oncomirs) in uveal 
melanoma using FFPE specimens by comparing miRNA expression profiles between non-
invasive tumor and melanoma metastatic to the liver. They revealed 19 miRNAs that were 
expressed in non-metastatic melanoma but were absent in metastatic melanoma, and they 
revealed 11 miRNAs with the opposite expression pattern65.  
In addition to FFPE samples, blood samples have been used to identify the melanoma tumor 
biomarkers66. Leidinger et al screened almost 900 human miRNAs, 55 blood samples, 
including 20 samples of healthy individuals, 24 samples of melanoma patients as test set, 
and 11 samples of melanoma patients as independent validation set. They identified 51 
altered miRNAs (21 down-regulated miRNAs and 30 up-regulated miRNAs) that can 
potentially distinguish melanoma patients from healthy controls. More excitingly, the panel 
consisting of 16 deregulated miRNAs can reach a classification accuracy of 97.4%, a 
specificity of 95%, and a sensitivity of 98.9%. Therefore, this study again demonstrates that 
signatures of miRNA expression can act as useful biomarkers for melanoma66  
Kanemaru et al, in particular, indentified the serum level of miR-221 as a new tumor marker 
in patients with malignant melanoma67. MiR-221 is usually up-regulated in malignant 
melanoma cells as we discussed earlier. By measuring the miR-221 levels in serum from 94 
malignant melanoma patients and 20 healthy controls, they found that the circulating miR-
221 was detectable and could be quantified in serum samples; the serum levels of miR-221 
were significantly increased in malignant melanoma patients when compared to healthy 
controls. Among the malignant melanoma patients, the miR-221 levels were significantly 
increased in patients with advanced melanoma compared to those with melanoma in situ, 
and the levels were correlated with tumor thickness. Moreover, they also revealed a 
decreasing tendency for the miR-221 levels along with the surgical removal of the primary 
tumor, but miR-221 was found to increase again at recurrence, which strongly suggested 
that circulating miR-221 may be useful not only for diagnosing malignant melanoma and for 
differentiating melanoma with different stages, but it could also be useful as a prognostic 
marker for patients with malignant melanoma67. 
5.2 Prognostic miRNAs 
Like miR-221, some other miRNAs have been reported for their prognostic signatures in 
melanoma. Worley et al. were the first to use a genome-wide, microarray-based approach to 
investigate the value of miRNA expression patterns in predicting metastatic risk in uveal 
melanoma. They found the most significant discriminator to classify low and high 
metastatic risk was let-7b and miR-199a expression. A classifier system that included the top 
six miRNA discriminators accurately distinguished melanoma patient tissues with high 
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metastatic propensity with 100% sensitivity and specificity23. Satzger et al. found that miR-
15b and miR-210 were significantly up-regulated in parallel with the down-regulation of 
miR-34a in melanoma compared to nevi. These three miRNAs were then analyzed in 128 
primary melanoma patients, including detailed clinical follow-up information; only the high 
expression of miR-15b was significantly correlated with the poor recurrence-free survival 
and overall survival by the univariate Kaplan-Meier and the multivariate Cox analyses. 
Furthermore, the transfection of anti-miR-15b into melanoma cells led to a reduced tumor 
cell proliferation and an increased apoptosis. Their results showed that miR-15b might be a 
novel melanoma biomarker contributing to poor prognosis and tumorigenesis68. Segura et 
al. identified the signature of a panel of miRNAs for predicting post-recurrence survival in 
metastatic melanoma by analyzing 59 formalin-fixed paraffin-embedded melanoma 
metastasis samples. Eighteen over-expressed miRNAs are significantly correlated with 
longer survival (>18 months). The signature of a six-miRNA panel (miR-150, miR342-3p, 
miR-455-3p, miR-145, miR-155, and miR-497) can have a better advantage to classify stage III 
patients into different  prognostic categories because it is an independent predictor of 
survival69. Additionally, the down-regulation of miR-191 and the up-regulation of miR-193b 
were reported to be associated with poor melanoma-specific survival70.  
5.3 Therapeutic miRNAs 
Since miRNAs are critical in regulating many cellular events and are highly deregulated in 
various cancers, including melanoma, it is likely that miRNAs could be effective targets for 
treatment. The basic strategies of miRNA-based therapeutics are: first, delivering highly 
expressed miRNAs that are tolerated in normal tissues but are lost in diseased cells , which 
may provide a general strategy for miRNA replacement therapies71; and second, using specific 
compounds targets aberrant oncogenic miRNAs, especially for over-expressed miRNAs. 
Sun et al. recently found that genistein, an isoflavone isolated from soybeans, inhibited 
human uveal melanoma cells growth in vitro and in vivo and altered the expression of miR-
27a and its target gene zinc finger and BTB domain containing 10 (ZBTB10), hinting at the 
contributions of miR-27a to genistein’s inhibitory effect on melanoma growth72. Das et al. 
found that human polynucleotide phosphorylase (hPNPase(old-35)), a type I IFN-inducible 
3'-5' exoribonuclease, can specifically down-regulate the expression of miR-221, a regulator 
of p27(kip1) and usually over-expressed in melanoma, as stated previously. This study 
implied that targeting over-expression of hPNPase(old-35) might provide an effective 
therapeutic strategy for miR-221-overexpressing and IFN-resistant tumors, such as 
melanoma73. MiR-137 acted as a tumor suppressor and usually decreased in uveal 
melanoma as previously described. Chen et al described one avenue to increase the 
expression levels of miR-137 through treatment with a DNA hypomethylating agent, 5-aza-
2'-deoxycytidine, or a histone deacetylase inhibitor, trichostatin A, for down-regulating its 
cognate target genes MITF and CDK638. MiR-182 is a pro-metastatic miRNA frequently 
over-expressed in melanoma. Huynh et al. assessed the effect of anti-miR-182 
oligonucleotides in a mouse model with melanoma liver metastasis and confirmed that miR-
182 levels were effectively down-regulated in the tumors of anti-miR-treated mice. This 
study implies that anti-miR may be a promising therapeutic strategy for metastatic 
melanoma74. Targeted delivery of RNA-based therapeutics for cancer therapy remains a 
challenge. By developing an improved liposome-polycation-hyaluronic acid (LPH) 
nanoparticle vehicle, Chen et al. reported that miR-34a was successfully delivered to B16-
F10 melanoma lung metastasis-bearing mice, and it could specifically suppress the 
surviving expression in the metastatic tumor and reduced tumor load in the lung75.  
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Progression  miRNA Target(s)
Regulatory 
Factor 
Associations 
Melanocyte  
 
     ↓ 
 
Primary 
Melanoma 
↓ 
let-7a
let-7b
ITGB3
CCND1
 
↓ Migration, invasion
↓ Proliferation, differentiation 
miR-137 MITF ↓ Cell migration, invasion and survival 
miR-155 ↑ Proliferation
miR-324-5p
miR-34a MET 
Promoter 
methylation
↓Proliferation 
 
↑ 
miR-106a
miR-126  
miR-133a
miR-141
miR-145  
miR-15b ↑ Proliferation, survival
miR-200c                        Migration style transition 
miR-27b
miR-210 MNT ↑ Proliferation 
  
 
Primary 
Melanoma  
 
      ↓ 
 
Metastasis 
↓ 
miR-126
miR-200c 
miR-141 
miR-133a
   
miR-34a
miR-199a* c-Met ↓ Cell migration, invasion and survival 
miR-34b/c c-Met ↓ Cell migration, invasion and survival 
 
↑ 
miR-106a
miR-133a
miR-199a*
miR-182 
MITF, 
FOXO3
 ↑ Migration, invasion and survival 
let-7b
  
Melanocyte 
 
      ↓ 
 
Metastasis 
↓ 
miR-133a
miR-155 ↓ Proliferation, survival
miR-193b
miR-196a 
HOX-C8 
HOX-B7
 ↓Invasion 
 
↑ 
miR-133a
miR-17-5p
miR-18a
miR-19a/b
miR-
221/222
c-Kit, p27 PLZF 
↑ Proliferation, invasion; ↓ 
differentiation
miR-532-5p RUNX3 ↑Invasion
miR-20a
miR-92a
Table 1. MicroRNAs in melanoma progression 
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6. Summary 
There were approximately 40 publications from the past year and a half that reported the 
involvement of miRNA in melanoma research from both laboratory and clinical settings, 
which evidences the perspective of miRNA as one of the most valuable biomarkers and 
therapeutic targets in current melanoma research. We are pleased to find the that research 
trend of miRNA and melanoma has changed from solely searching altered specific miRNAs 
to exploring molecular networks and connections between miRNAs and signaling pathways 
involved in the progression of melanoma (Table 1). Certainly, a better understanding of the 
biological machinery of miRNA function will allow us to visibly observe the genetic impacts 
on carcinogenesis and to explore effective therapeutic strategies for conquering melanoma 
in the near future. 
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